# US 2010/0136119 A1 · Controlled-release preparation containing cilostazol and process for the preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136119 A1
- Document ID: US20100136119A1
- Status: Published application
- Kind: A1
- Application number: 12/527,024
- Filed: 2008-02-15
- Published: 2010-06-03
- Earliest claimed: 2007-02-16
- Assignees: Amorepacific Corporation; Pacific Pharmaceutical Co., Ltd.
- Inventors: Jin Woo Park
- Web page: https://patentgrep.com/patent/US20100136119A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A controlled release preparation which comprises particles containing cilostazol or its pharmaceutically acceptable salt dispersed in a solubilizing agent and an erodible material encasing said particles which is capable of forming a hydrogel, can maintain a constant level of cilostazol in the blood through its slow release during its prolonged residence time in the stomach and intestines, thereby minimizing adverse effects caused by rapid release of the drug or solubilizing agent.

## Claims

### Claim 1

A controlled release preparation of cilostazol which comprises:
(A) particles comprising cilostazol or its pharmaceutically acceptable salt uniformly dispersed in a solubilizing agent, and
(B) an erodible material for forming a hydrogel in which said particles are dispersed therein.

### Claim 2 (depends on 1)

The controlled release preparation of claim 1, which comprises the cilostazol or its pharmaceutically acceptable salt in an amount ranging from 10 to 80% by weight; the solubilizing agent in an amount ranging from 0.1 to 50% by weight; and the erodible material for forming a hydrogel in an amount ranging from 5 to 80% by weight, based on the total weight of the preparation.

### Claim 3 (depends on 1)

The controlled release preparation of claim 1, wherein the solubilizing agent is selected from the group consisting of polyvinylpyrrolidone, copovidone, polyethyleneglycol, hydroxyalkylcellulose, hydroxypropylmethylcellulose, poloxamer, polyvinylalcohol, cyclodextrin, surfactant, and a mixture thereof.

### Claim 4 (depends on 3)

The controlled release preparation of claim 3, wherein the surfactant is selected from the group consisting of poly(oxyethylene)sorbitan fatty acid ester, poly(oxyethylene)stearate, poly(oxyethylene)alkylether, polyglycolized glyceride, poly(oxyethylene)castor oil, sorbitan fatty acid ester, poloxamer, fatty acid salt, bile salt, alkylsulfate, lecithin, mixed micelles of bile salt and lecithin, sugar ester vitamin E(polyethylene glycol 1000)succinate (TPGS), sodium lauryl sulfate, and a mixture thereof.

### Claim 5 (depends on 1)

The controlled release preparation of claim 1, wherein the erodible material for forming the hydrogel is selected from the group consisting of polyethyleneoxide, hydroxyalkylcellulose, hydroxypropyl alkylcellulose, polyvinylalcohol, polyvinylpyrrolidone, sodium carboxymethyl cellulose, propylene glycol alginate, carbopol, sodium alginate, xanthan gum, locust bean gum, cellulose gum, gellan gum, tragacanth gum, karaya gum, gua gum, acasia gum, and a mixture thereof.

### Claim 6 (depends on 1)

The controlled release preparation of claim 1, which further comprises a pharmaceutically acceptable additive.

### Claim 7 (depends on 6)

The controlled release preparation of claim 6, wherein the pharmaceutically acceptable additive is selected from the group consisting of a diluent, a binding agent, a swelling agent, a lubricant, and a mixture thereof.

### Claim 8 (depends on 7)

The controlled release preparation of claim 7, wherein the diluent is selected from the group consisting of lactose, dextrin, mannitol, sorbitol, starch, microcrystalline cellulose, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, calcium carbonate, sugars, and a mixture thereof.

### Claim 9 (depends on 7)

The controlled release preparation of claim 7, wherein the binding agent is selected from the group consisting of polyvinylpyrrolidone, copovidone, gelatin, starch, sucrose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylalkylcellulose, and a mixture thereof.

### Claim 10 (depends on 7)

The controlled release preparation of claim 7, wherein the swelling agent is selected from the group consisting of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethylcellulose, cross-linked calcium carboxymethylcellulose, cross-linked carboxymethylcellulose, sodium starch glycolate, carboxymethyl starch, sodium carboxymethyl starch, potassium methacrylate-divinylbenzene copolymer, amylose, cross-linked amylose, a starch derivative, microcrystalline cellulose, a cellulose derivative, cyclodextrin, a dextrin derivative, and a mixture thereof.

### Claim 11 (depends on 7)

The controlled release preparation of claim 7, wherein the lubricant is selected from the group consisting of stearic acid, stearate, talc, corn starch, carnauba wax, light anhydrous silicic acid, magnesium silicate, synthetic aluminum silicate, hardened oil, white lead, titanium oxide, microcrystallinecellulose, macrogol 4000 and 6000, isopropyl myristate, calcium hydrogen phosphate, and a mixture thereof.

### Claim 12 (depends on 1)

The controlled release preparation of claim 1, which further comprise a coating layer containing a coating agent.

### Claim 13 (depends on 12)

The controlled release preparation of claim 12, wherein the coating agent is selected from the group consisting of ethylcellulose, shellac, ammonio methacrylate copolymer, polyvinylacetate, polyvinylpyrrolidone, polyvinylalcohol, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxybutylcellulose, hydroxypentylcellulose, hydroxypropylmethylcellulose, hydroxypropylbutylcellulose, hydroxypropylpentylcellulose, hydroxyalkylcellulosephthalate, sodium celluloseacetatephthalate, celluloseacetylphthalate, celluloseetherphthalate, anionic copolymer of methacrylic acid and methyl or ethyl ester methacrylate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetylsuccinate, cellulose acetylphthalate, Opadry, and a mixture thereof.

### Claim 14 (depends on 1)

A method for preparing the controlled release preparation of cilostazol of claim 1, which comprises:
(1) mixing cilostazol or its pharmaceutically acceptable salt with a solubilizing agent, and subjecting the resulting mixture to granulation using a solid dispersing method to produce particles; and
(2) adding an erodible material for forming a hydrogel to the particles obtained in step (1), and subjecting the resulting mixture to granulation to produce granules having the particles encased therein.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cilostazol or its pharmaceutically acceptable salt is used in an amount ranging from 10 to 80% by weight based on the total weight of the preparation.

### Claim 16 (depends on 14)

The method of claim 14, wherein the solubilizing agent is used in an amount ranging from 0.1 to 50% by weight based on the total weight of the preparation.

### Claim 17 (depends on 14)

The method of claim 14, wherein the erodible material for forming the hydrogel is used in an amount ranging from 5 to 80% by weight based on the total weight of the preparation.

### Claim 18 (depends on 14)

The method of claim 14, which further comprises adding a pharmaceutically acceptable additive to the mixture before performing step (1) or (2), or to the granules obtained in step (2).

### Claim 19 (depends on 18)

The method of claim 18, wherein the pharmaceutically acceptable additive is selected from the group consisting of a diluent, a binding agent, a swelling agent, a lubricant, and a mixture thereof.

### Claim 20 (depends on 14)

The method of claim 14, which further comprises coating the granules obtained in step (2) with a coating agent.
